KyungDong Pharm Co., Ltd. launches the combined diabetes treatment drug ‘Pictomin Tablets (pioglitazone 15mg & metformin hydrochloride 850mg)’ on October 1, 2017.

‘Pictomin Tablets’ is a combination medicine made by combining the advantages of pioglitazone, which is effective in improving insulin resistance, and metformin, which is effective in reducing blood sugar levels by preventing excessive production of glucose in the liver.

‘Pictomin Tablets’ are administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with non-insulin-dependent diabetes (type 2). It shows excellent blood sugar lowering properties and is an effective product in improving serum lipids, which is expected to be helpful in treating diabetes.

♤ Product Information ♤

 

Product Name

Pictomin Tablets

Ingredient content

16.53 mg of pioglitazone hydrochloride in 1 tablet (15 mg as pioglitazone)

Metformin hydrochloride 850mg

Indications

1. Cases where sufficient blood sugar control cannot be achieved with metformin or pioglitazone monotherapy

2. Alternative to pioglitazone and metformin combination therapy

Dosage and usage

In the treatment of patients with type 2 diabetes, the dosage of this drug is the maximum dosage of each ingredient.

Effectiveness and tolerability are confirmed within a range not exceeding 30 mg of pioglitazone and 2500 mg of metformin.

It should be individualized on the basis of evidence. The initial dose of this drug should be based on the patient's current treatment regimen.

1. Patients whose blood sugar level is not adequately controlled with metformin and pioglitazone monotherapy:

It should be based on the dose of metformin or pioglitazone currently being administered.

Start with one tablet per day and gradually adjust the dose by evaluating the appropriateness of the treatment response.

2. Patients switching from combination therapy of pioglitazone and metformin:

Patients switching from combination therapy of pioglitazone and metformin to this drug should use Pioglitazone.

You can start with your existing dose of John and Metformin. Previously used other oral hypoglycemic agents

No studies have been conducted to examine the safety and effectiveness of switching from this drug to this drug.

didn't Any change in type 2 diabetes treatment regimen may cause changes in blood sugar control.

Therefore, caution must be exercised and appropriate monitoring must be carried out.

3. Patients with renal impairment: All dosage adjustments should be based on careful evaluation of renal function.

In general, elderly, debilitated, and nutritionally deficient patients may receive the maximum dose of this drug.

The dosage should not be increased.

Reimbursement Prices

714 won/tablet

Reimbursement Code

648103990

Packaging unit

28 tablets

※ Please refer to the product manual for other details such as precautions for use.